Chronic exposure to cigarette smoke transiently worsens the disease course in a mouse model of pulmonary paracoccidioidomycosis

ABSTRACT Paracoccidioidomycosis (PCM) may present as an acute/subacute clinical form, characterized by a progressive disease arising from the airborne initial infection, or, most often, as an asymptomatic or subclinical infection that may manifest later during an individual’s life, the chronic form. Epidemiological studies show the existence of a strong association between smoking and the development of the chronic form. Current evidence demonstrates that cigarette smoke (CS) has immunosuppressive properties that could be implicated in the increasing susceptibility to the chronic form of PCM. To address this issue, we developed a murine model of a non-progressive pulmonary form of PCM that was exposed to CS at a magnitude that mimicked a moderate smoker. The chronic CS exposure started after 2 weeks and lasted up until 20 weeks post-infection, with the aim of mimicking human natural history, since it is estimated that individuals from endemic areas are infected early in life. The control group consisted of infected but not CS-exposed mice. We assessed the lung fungal burden (colony forming units [CFU]) and the area affected by the granulomatous inflammatory response, fungal dissemination to spleen and liver, and, by immunohistochemistry, the presence of CD4 and CD8 lymphocytes, CD68 and MAC-2 macrophages, and IFN-γ, IL-10 and TNF expressing cells within the granulomatous response. We detected a CS effect as early as 2 weeks after exposure (four weeks post-infection) when the lung CFU of exposed animals was significantly higher than in their non-exposed counterparts. At 12 weeks, the CS-exposed animals presented a more severe disease, as witnessed by the persistent higher lung fungal load (although it did not reach statistical significance [ p = 0.054]), greater dissemination to other organs, greater affected area of the lung, decreased IFN-γ/IL-10 ratio, and higher TNF expression within the granulomas, compared with CS-non-exposed mice. The number of CD4 and CD8 lymphocytes infiltrating the granulomas was similar between both mice groups, but there was a decrease in the number of MAC-2+ macrophages. No difference was noted in the CD68+ macrophage number. However, the follow-up in week 20 showed that the immunological effects of exposure to CS ceased, with both CS and NCS mice showing the same infectious features, i.e., a trend for resolution of the infection. In conclusion, we show that chronic CS-exposure alters the course of the disease in an experimental model of subclinical pulmonary PCM, confirming the epidemiological link between CS-exposure and the chronic form of PCM. However, we also show that this effect is transitory, being detected between 4- and 12-weeks post-infection but not thereafter. The possible immune mechanisms that mediate this effect and the reasons for its transitory effect are discussed.

Palavras-chave

Paracoccidioidomycosis, Cigarette smoke, Subclinical infection, Immune response, Risk factors

URI

https://observatorio.fm.usp.br/handle/OPI/55834

Referências

Amorim BC, 2020, MICROBES INFECT, V22, P137, DOI 10.1016/j.micinf.2019.11.001
Benard G, 2001, CYTOKINE, V13, P248, DOI 10.1006/cyto.2000.0824
Benard G, 2021, Open Forum Infect Dis, V8
Biselli P.J.C., 2011, Braz J Med Biol Res, V44, P460, DOI 10.1590/S0100-879X2011007500040
BRUMMER E, 1990, MYCOPATHOLOGIA, V109, P13, DOI 10.1007/BF00437001
Cacere CR, 2002, CLIN IMMUNOL, V105, P215, DOI 10.1006/clim.2002.5272
CALICH VLG, 1985, BRIT J EXP PATHOL, V66, P585
Cano LE, 1998, INFECT IMMUN, V66, P800, DOI 10.1128/IAI.66.2.800-806.1998
Chistiakov DA, 2017, LAB INVEST, V97, P4, DOI 10.1038/labinvest.2016.116
Costa TA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002512
de Castro LF, 2013, J INFECTION, V67, P470, DOI 10.1016/j.jinf.2013.07.019
de Pina DR, 2017, QUANT IMAG MED SURG, V7, P318, DOI 10.21037/qims.2017.06.04
Santos Werbena Aguiar dos, 2003, Cad. Saúde Pública, V19, P245, DOI 10.1590/S0102-311X2003000100027
Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020
Franco M, 1987, Rev Soc Bras Med Trop, V20, P129, DOI 10.1590/S0037-86821987000200012
Gentry-Nielsen MJ, 2004, ALCOHOL CLIN EXP RES, V28, P1120, DOI 10.1097/01.ALC.0000136383.45378.91
Gonzalez-Juarrero M, 2001, INFECT IMMUN, V69, P1722, DOI 10.1128/IAI.69.3.1722-1728.2001
Hernandez CP, 2013, CELL IMMUNOL, V282, P38, DOI 10.1016/j.cellimm.2013.04.005
HOLT PG, 1977, BACTERIOL REV, V41, P205, DOI 10.1128/MMBR.41.1.205-216.1977
LEMLE A, 1983, CHEST, V83, P827, DOI 10.1378/chest.83.5.827
Lopez-Hernandez Y, 2018, EXP LUNG RES, V44, P113, DOI 10.1080/01902148.2018.1444824
MARTINEZ Roberto, 2015, Rev. Inst. Med. trop. S. Paulo, V57, P11, DOI 10.1590/S0036-46652015000700004
Paniago Anamaria Mello Miranda, 2003, Rev. Soc. Bras. Med. Trop., V36, P455, DOI 10.1590/S0037-86822003000400004
Qiu FF, 2017, ONCOTARGET, V8, P268, DOI 10.18632/oncotarget.13613
Quagliato Júnior Reynaldo, 2007, J. bras. pneumol., V33, P295, DOI 10.1590/S1806-37132007000300011
Quan DH, 2022, Eur Respir Rev, V31
Shang SB, 2011, J INFECT DIS, V203, P1240, DOI 10.1093/infdis/jir009
Singer-Vermes L M, 1993, Arch Med Res, V24, P239
STEWART RD, 1974, JAMA-J AM MED ASSOC, V229, P1187, DOI 10.1001/jama.229.9.1187
Strzelak A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051033
TUDER RM, 1985, MYCOPATHOLOGIA, V92, P179, DOI 10.1007/BF00437631
Vieira Gabriel de Deus, 2014, Rev. Soc. Bras. Med. Trop., V47, P63, DOI 10.1590/0037-8682-0225-2013

Coleções

Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/01
Artigos e Materiais de Revistas Científicas - LIM/06
Artigos e Materiais de Revistas Científicas - LIM/53

Carregar mais

Página do item completo